EUVIMEDEUVIMED entdecken
Randomisierte kontrollierte StudieKlinische Studie (Phase III)Multizentrische StudieVergleichsstudie

Fixed-Duration Acalabrutinib Combinations in Untreated Chronic Lymphocytic Leukemia

Jennifer R Brown iD, John F Seymour iD, Wojciech Jurczak, Andrew Aw, Malgorzata Wach, Arpad Illes, Alessandra Tedeschi, Carolyn Owen, Alan Skarbnik, Daniel Lysak, Ki-Seong Eom, Martin Šimkovič iD und 10 weitere

New England Journal of Medicine · 20.02.2025 · 392 (8) · 748-762

DOI: 10.1056/nejmoa2409804 ↗

Kurz gefasst

Randomisierte kontrollierte Studie in der Zeitschrift New England Journal of Medicine, erschienen am 20.02.2025. Verfasst von Jennifer R Brown und 21 weiteren Autor:innen. Beteiligte Einrichtung: Dana-Farber Cancer Institute, Boston. Hauptthemen laut MEDLINE: Antineoplastic Combined Chemotherapy Protocols, Benzamides, Leukemia, Lymphocytic, Chronic, B-Cell, Pyrazines. Die Arbeit wurde bisher 144-mal zitiert (Crossref) und nennt 22 Literaturangaben. Gefördert von: AstraZeneca.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Kein Abstract verfügbar.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Antineoplastic Combined Chemotherapy ProtocolsBenzamidesLeukemia, Lymphocytic, Chronic, B-CellPyrazinesSulfonamidesAdultAgedAged, 80 and overFemaleHumansMaleMiddle AgedAntibodies, Monoclonal, HumanizedBendamustine HydrochlorideBridged Bicyclo Compounds, HeterocyclicCyclophosphamideIntention to Treat AnalysisProgression-Free SurvivalRituximabVidarabineKaplan-Meier EstimateTreatment Outcome

Substanzen

acalabrutinibAntibodies, Monoclonal, HumanizedBendamustine HydrochlorideBenzamidesBridged Bicyclo Compounds, HeterocyclicCyclophosphamidefludarabineobinutuzumabPyrazinesRituximab

Autor:innen und Institutionen

  • Dana-Farber Cancer Institute, Boston.
  • Peter MacCallum Cancer Centre, University of Melbourne, Melbourne, VIC, Australia.
  • Royal Melbourne Hospital, University of Melbourne, Melbourne, VIC, Australia.
  • Maria Sklodowska-Curie National Institute of Oncology, Kraków, Poland.
  • University of Ottawa, Ottawa.
  • Medical University of Lublin, Lublin, Poland.

ORCID-Profile: Jennifer R Brown, John F Seymour, Martin Šimkovič

Förderung

  • AstraZeneca

Zitieren

APA

Brown, J. R., Seymour, J. F., Jurczak, W., Aw, A., Wach, M., Illes, A., Tedeschi, A., Owen, C., Skarbnik, A., Lysak, D., Eom, K. S., Šimkovič, M., Pavlovsky, M. A., Kater, A. P., Eichhorst, B., Miller, K., Munugalavadla, V., Yu, T., de Borja, M., …, & AMPLIFY Investigators (2025). Fixed-Duration Acalabrutinib Combinations in Untreated Chronic Lymphocytic Leukemia. New England Journal of Medicine, 392(8), 748-762. https://doi.org/10.1056/nejmoa2409804

Vancouver

Brown JR, Seymour JF, Jurczak W, Aw A, Wach M, Illes A, et al. Fixed-Duration Acalabrutinib Combinations in Untreated Chronic Lymphocytic Leukemia. New England Journal of Medicine. 2025;392(8):748-762. doi:10.1056/nejmoa2409804

BibTeX
@article{Brown2025,
  author = {Brown, Jennifer R and Seymour, John F and Jurczak, Wojciech and Aw, Andrew and Wach, Malgorzata and Illes, Arpad and Tedeschi, Alessandra and Owen, Carolyn and Skarbnik, Alan and Lysak, Daniel and Eom, Ki-Seong and Šimkovič, Martin and Pavlovsky, Miguel Arturo and Kater, Arnon Philip and Eichhorst, Barbara and Miller, Kara and Munugalavadla, Veerendra and Yu, Ting and de Borja, Marianne and Ghia, Paolo and AMPLIFY investigators, AMPLIFY investigators and AMPLIFY Investigators, AMPLIFY Investigators},
  title = {Fixed-Duration Acalabrutinib Combinations in Untreated Chronic Lymphocytic Leukemia},
  journal = {New England Journal of Medicine},
  year = {2025},
  volume = {392},
  number = {8},
  pages = {748--762},
  doi = {10.1056/nejmoa2409804}
}
Kostenlos starten →